Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2021 call → NOThe question asks whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket — with three conditions: (1) paying now for something not yet earning, (2) the wait is the company's main current work, (3) the far side is a specific, near-dated, already-visible event within roughly a year, depending on work already in motion. Let me examine the transcript for such a situation. The company's main topics: HETLIOZ commercial performance, payer challenges, SMS launch, Fanapt bipolar study, tradipitant gastroparesis study results. The tradipitant program: they completed a Phase III study, results were mixed, they are proposing analytic approaches, and they intend to collaborate with FDA. But there's no defined waiting period with a near-dated event. They say "it is too early to answer this question" about next steps. No specific near-dated event. The Fanapt bipolar study: "over 50% enrolled and expected to complete enrollment by the end of 2022" — that's a trial in progress, but is the company "paying now for something not yet earning"? R&D expenses are ongoing, but this is normal clinical development, not a defined waiting period with a specific near-dated crossing that changes earning capability. Also, the completion of enrollment is not the earning event; approval and launch would be much later. The SMS launch: "More than 50 patients with SMS are currently on treatment" — so it's already launched and earning. Not a waiting period. The payer challenges: they are working to resolve access issues, but this is not a self-funded waiting period before a specific arrival; it's an ongoing commercial challenge. The HETLIOZ guidance: they expect reimbursement challenges to impact near-term performance, but they are optimistic about longer-term. No specific near-dated event. The tradipitant program: they spent six years recruiting patients, the study is done, results are mixed, and they are proposing analyses. The "far side" would be FDA approval, which is not near-dated or already visible, and depends on regulatory decisions not yet made. None of these fit the description of a company currently bearing a self-funded cost for a specific near-dated arrival that is already largely paid for. The tradipitant program is a completed trial with uncertain regulatory path.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.